摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Methyl-1-propylsulfonylpiperidine | 57150-58-0

中文名称
——
中文别名
——
英文名称
4-Methyl-1-propylsulfonylpiperidine
英文别名
——
4-Methyl-1-propylsulfonylpiperidine化学式
CAS
57150-58-0
化学式
C9H19NO2S
mdl
MFCD16172043
分子量
205.32
InChiKey
SEITWHKZTGEZOY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    45.8
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • [EN] NOVEL COMPOUNDS AS MODULATORS OF GPR-119<br/>[FR] NOUVEAUX COMPOSES UTILISES COMME MODULATEURS DE GPR-119
    申请人:RHIZEN PHARMACEUTICALS SA
    公开号:WO2012170867A1
    公开(公告)日:2012-12-13
    The present invention relates to novel compounds of formula (A) and (B) as modulators of GPR-119, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of GPR-119 mediated diseases or disorders with them.
    本发明涉及公式(A)和(B)的新化合物作为GPR-119调节剂,其制备方法,含有它们的药物组合物,以及利用它们治疗、预防和/或改善GPR-119介导的疾病或疾病的方法。
  • Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S
    申请人:Wyatt Paul Graham
    公开号:US20080306069A1
    公开(公告)日:2008-12-11
    The invention provides compounds of the formula (I), or salts, tautomers, N-oxides or solvates thereof wherein: R1 is selected from: (a) 2,6-dichlorophenyl; (b) 2,6-difluorophenyl; (c) a 2,3,6-trisubstituted phenyl group wherein the substituents for the phenyl group are selected from fluorine, chlorine, methyl and methoxy; (d) a group RO; (e) a group R a; (f) a group RIb; (g) a group RIc; (h) a group RId; and 0) 2,6-difluorophenylamino; wherein R) 0υ, r R>llaa, T Rj HbD, T R) HcC, r R>Iidα, r R>>2zaa, r R>22bD and RJ are as defined in the claims. The compounds have activity as inhibitors of cdk kinase (such as cdk1 or cdk2) and glycogen synthase kinase-3 activity.
    该发明提供了式(I)的化合物,或其盐、互变异构体、N-氧化物或溶剂化物,其中:R1选择自:(a)2,6-二氯苯基;(b)2,6-二氟苯基;(c)2,3,6-三取代苯基,其中苯基的取代基选择自氟、氯、甲基和甲氧基;(d)羟基取代基;(e)R a基;(f)RIb基;(g)RIc基;(h)RId基;和(i)2,6-二氟苯基氨基基;其中R) 0υ,r R>llaa,T Rj HbD,T R) HcC,r R>Iidα,r R>>2zaa,r R>22bD和RJ如权利要求所定义。该化合物具有作为cdk激酶(如cdk1或cdk2)和糖原合成酶激酶-3活性抑制剂的活性。
  • TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
    申请人:Babu Srinivasan
    公开号:US20110201593A1
    公开(公告)日:2011-08-18
    The invention provides novel compounds of formula I having the general formula: wherein R 1 , R 2 , R 3 , X and Y are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.
    本发明提供了具有以下一般式的新化合物I: 其中R1、R2、R3、X和Y如本文所述。因此,这些化合物可以在药学上可接受的组合物中提供,并用于治疗免疫或过度增生性疾病。
  • NOVEL COMPOUNDS AS MODULATORS OF GPR-119
    申请人:NAGARATHNAM Dhanapalan
    公开号:US20130045986A1
    公开(公告)日:2013-02-21
    The present invention relates to novel compounds of formula (A) and (B) as modulators of GPR-119, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of GPR-119 mediated diseases or disorders with them.
    本发明涉及一种公式(A)和(B)的新化合物,作为GPR-119的调节剂,其制备方法,包含它们的制药组合物以及使用它们治疗、预防和/或改善GPR-119介导的疾病或障碍的方法。
  • Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors
    申请人:Arrien Pharmaceuticals LLC
    公开号:US20160081989A1
    公开(公告)日:2016-03-24
    Compounds according to Formulas I, IA or IB: to pharmaceutically acceptable composition, salts thereof, their synthesis and their use as SIK2 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and/or disorders such as cancer, stroke, cardiovascular, obesity and type II diabetes.
    根据I、IA或IB公式的化合物:制备药学上可接受的组成,其盐,其合成方法及其用作SIK2抑制剂的用途,包括这些化合物和使用这些化合物治疗各种疾病和/或疾病的方法,如癌症、中风、心血管疾病、肥胖症和2型糖尿病。
查看更多